Grace Therapeutics (GRCE) Competitors

$2.19 -0.06 (-2.67%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$2.19 0.00 (-0.18%)

As of 09:26 AM Eastern

GRCE vs. GALT, DERM, EQ, ACOG, and CNTB

Should you buy Grace Therapeutics stock or one of its competitors? MarketBeat compares Grace Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Grace Therapeutics include Galectin Therapeutics (GALT), Journey Medical (DERM), Equillium (EQ), Alpha Cognition (ACOG), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry.

How does Grace Therapeutics compare to Galectin Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.48	N/A

In the previous week, Galectin Therapeutics had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Galectin Therapeutics and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.95 beat Galectin Therapeutics' score of 0.63 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics' return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Galectin Therapeutics	N/A	N/A	-214.23%

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Grace Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 173.97%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 368.09%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Summary

Galectin Therapeutics beats Grace Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Grace Therapeutics compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 15.0% of Journey Medical shares are owned by insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Journey Medical presently has a consensus price target of $13.00, indicating a potential upside of 104.72%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 173.97%. Given Grace Therapeutics' higher probable upside, analysts clearly believe Grace Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics has lower revenue, but higher earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.81	-$11.43M	-$0.47	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

In the previous week, Journey Medical had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 12 mentions for Journey Medical and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.95 beat Journey Medical's score of 0.01 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Grace Therapeutics' return on equity of -15.58% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-37.36%	-11.02%
Grace Therapeutics	N/A	-15.58%	-14.51%

Journey Medical has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Summary

Journey Medical beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to Equillium?

Equillium (NASDAQ:EQ) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

27.1% of Equillium shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 11.1% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Equillium presently has a consensus price target of $7.67, indicating a potential upside of 196.01%. Grace Therapeutics has a consensus price target of $6.00, indicating a potential upside of 173.97%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Grace Therapeutics has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.98	-$22.40M	-$0.32	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

In the previous week, Equillium had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Equillium and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.95 beat Equillium's score of -0.23 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grace Therapeutics' return on equity of -15.58% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-88.50%	-72.55%
Grace Therapeutics	N/A	-15.58%	-14.51%

Equillium has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Summary

Equillium beats Grace Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Grace Therapeutics has lower revenue, but higher earnings than Alpha Cognition. Grace Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.10	-$20.67M	-$1.16	N/A
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A

Alpha Cognition presently has a consensus price target of $16.00, suggesting a potential upside of 181.69%. Grace Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 173.97%. Given Alpha Cognition's stronger consensus rating and higher possible upside, research analysts clearly believe Alpha Cognition is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alpha Cognition had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Alpha Cognition and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.95 beat Alpha Cognition's score of 0.88 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.1% of Grace Therapeutics shares are held by institutional investors. 14.0% of Alpha Cognition shares are held by insiders. Comparatively, 11.1% of Grace Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Grace Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -202.23%. Grace Therapeutics' return on equity of -15.58% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-202.23%	-55.71%	-43.78%
Grace Therapeutics	N/A	-15.58%	-14.51%

Alpha Cognition has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Summary

Alpha Cognition beats Grace Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Grace Therapeutics compare to Connect Biopharma?

Grace Therapeutics (NASDAQ:GRCE) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Grace Therapeutics has higher earnings, but lower revenue than Connect Biopharma. Grace Therapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Connect Biopharma	$60K	2,602.35	-$55.48M	-$1.15	N/A

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 173.97%. Connect Biopharma has a consensus price target of $8.67, suggesting a potential upside of 249.46%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Connect Biopharma had 12 more articles in the media than Grace Therapeutics. MarketBeat recorded 14 mentions for Connect Biopharma and 2 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.95 beat Connect Biopharma's score of -0.51 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Grace Therapeutics' return on equity of -15.58% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Connect Biopharma	N/A	-122.29%	-97.07%

Grace Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

Summary

Connect Biopharma beats Grace Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRCE vs. The Competition

Export

Metric	Grace Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.82M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-5.47	18.47	20.66	25.63
Price / Sales	N/A	294.84	544.27	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.45	6.93	9.87	6.97
Net Income	-$9.57M	$24.11M	$3.55B	$333.62M
7 Day Performance	-6.41%	5.89%	1.67%	1.09%
1 Month Performance	-49.77%	-0.91%	0.46%	3.08%
1 Year Performance	-19.19%	74.58%	39.37%	35.68%

Grace Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRCE Grace Therapeutics	3.0128 of 5 stars	$2.19 -2.7%	$6.00 +174.0%	-18.9%	$34.82M	N/A	N/A	N/A	Positive News
GALT Galectin Therapeutics	1.7956 of 5 stars	$2.10 -0.5%	$11.00 +423.8%	+80.8%	$138.90M	N/A	N/A	9	News Coverage Earnings Report
DERM Journey Medical	2.3231 of 5 stars	$5.07 +1.4%	$13.00 +156.4%	+6.4%	$136.65M	$61.86M	N/A	90	News Coverage Earnings Report Gap Up
EQ Equillium	2.5735 of 5 stars	$2.11 -1.4%	$7.67 +263.3%	+593.8%	$135.30M	$41.10M	N/A	40	Positive News Earnings Report
ACOG Alpha Cognition	3.5963 of 5 stars	$6.10 +0.2%	$16.00 +162.3%	-17.2%	$132.60M	$10.22M	N/A	N/A	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRCE) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grace Therapeutics (GRCE) Competitors

GRCE vs. GALT, DERM, EQ, ACOG, and CNTB

How does Grace Therapeutics compare to Galectin Therapeutics?

Summary

How does Grace Therapeutics compare to Journey Medical?

Summary

How does Grace Therapeutics compare to Equillium?

Summary

How does Grace Therapeutics compare to Alpha Cognition?

Summary

How does Grace Therapeutics compare to Connect Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grace Therapeutics (GRCE) Competitors

GRCE vs. GALT, DERM, EQ, ACOG, and CNTB

How does Grace Therapeutics compare to Galectin Therapeutics?

Which has preferable earnings and valuation, GRCE or GALT?

Does the media refer more to GRCE or GALT?

Is GRCE or GALT more profitable?

Do insiders & institutionals have more ownership in GRCE or GALT?

Do analysts recommend GRCE or GALT?

Which has more risk and volatility, GRCE or GALT?

Summary

How does Grace Therapeutics compare to Journey Medical?

Do institutionals & insiders have more ownership in DERM or GRCE?

Do analysts prefer DERM or GRCE?

Which has higher earnings & valuation, DERM or GRCE?

Does the media prefer DERM or GRCE?

Is DERM or GRCE more profitable?

Which has more risk & volatility, DERM or GRCE?

Summary

How does Grace Therapeutics compare to Equillium?

Do institutionals & insiders have more ownership in EQ or GRCE?

Do analysts prefer EQ or GRCE?

Which has higher earnings & valuation, EQ or GRCE?

Does the media prefer EQ or GRCE?

Is EQ or GRCE more profitable?

Which has more risk & volatility, EQ or GRCE?

Summary

How does Grace Therapeutics compare to Alpha Cognition?

Which has better valuation & earnings, ACOG or GRCE?

Do analysts rate ACOG or GRCE?

Does the media favor ACOG or GRCE?

Do insiders and institutionals have more ownership in ACOG or GRCE?

Is ACOG or GRCE more profitable?

Which has more volatility & risk, ACOG or GRCE?

Summary

How does Grace Therapeutics compare to Connect Biopharma?

Which has preferable valuation and earnings, GRCE or CNTB?

Do analysts recommend GRCE or CNTB?

Does the media favor GRCE or CNTB?

Do institutionals and insiders hold more shares of GRCE or CNTB?

Is GRCE or CNTB more profitable?

Which has more risk & volatility, GRCE or CNTB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRCE vs. The Competition

Grace Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools